Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Protocol ID
TAK-620-2004
Disease (Sub Disease)
Cytomegalovirus (CMV)
Diagnosis Stage
Previously treated
Sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 17 Years
International registry ID's
NCT05319353
Back to Registry
Study Title A Phase 3 Open-label Single-arm Repeated-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Protocol ID TAK-620-2004
Disease (Sub Disease) Cytomegalovirus (CMV)
Diagnosis Stage Previously treated
Sponsor Takeda
Collaborators Takeda Development Center Americas, Inc.
Links https://clinicaltrials.gov/ct2/show/NCT05319353
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 3
Age Eligibility up to 17 Years
International registry ID's NCT05319353